Astellas Pharma Inc (ALPMF PINK) stock market data APIs
$10.5118
0(0%)
as of May 7, 2025
Astellas Pharma Inc Financial Data Overview
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Prev. Close
10.5118
Open
10.5118
High
10.5118
Low
10.5118
52 wk Range
8.405-11.8943
Market Cap
18 116 M
P/E Ratio
50.6
Shares Outstanding
1 790 M
Revenue
1 912 323 M
EPS
41.84
Dividends (Yield)
0.0538
Beta
0.166
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Astellas Pharma Inc data using free add-ons & libraries
Get Astellas Pharma Inc Fundamental Data
{
"General": {
"Code": "ALPMF",
"Type": "Common Stock",
"Name": "Astellas Pharma Inc",
"Exchange": "PINK",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG000BVK3G2",
"ISIN": null,
"CUSIP": null,
"CIK": "0001446390",
"EmployerIdNumber": null,
"FiscalYearEnd": "March",
"IPODate": null,
"InternationalDomestic": null,
"Sector": "Healthcare",
"Industry": "Drug Manufacturers - General",
"HomeCategory": null,
"IsDelisted": false,
"Description": "Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a..."
}
}Astellas Pharma Inc Fundamental data includes:
- Net Revenue: 1 912 323 M
- EBITDA: 431 680 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-25
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Astellas Pharma Inc News
New
Notice of Nominees for Directors
TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that during a meeting of its Board of Directors held today, it decid...
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
ARVO and RWC abstracts feature analyses on biomarkers, mechanism of disease, patient experience and other data from IZERVAY™ (avacincaptad pegol intravitreal solution) pivotal studies TOKYO, May ...
Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Astellas Pharma Inc. (ALPMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings e...
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Astellas Pharma Inc. (ALPMY) is a stock that can certainly grab t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
